U.S. Markets closed
  • S&P 500

    3,900.79
    -22.89 (-0.58%)
     
  • Dow 30

    31,253.13
    -236.94 (-0.75%)
     
  • Nasdaq

    11,388.50
    -29.66 (-0.26%)
     
  • Russell 2000

    1,776.22
    +1.38 (+0.08%)
     
  • Crude Oil

    111.44
    -0.77 (-0.69%)
     
  • Gold

    1,840.70
    -0.50 (-0.03%)
     
  • Silver

    21.91
    +0.00 (+0.01%)
     
  • EUR/USD

    1.0585
    -0.0002 (-0.0212%)
     
  • 10-Yr Bond

    2.8550
    -0.0310 (-1.07%)
     
  • Vix

    29.35
    -1.61 (-5.20%)
     
  • GBP/USD

    1.2468
    -0.0007 (-0.0524%)
     
  • USD/JPY

    127.7200
    -0.0740 (-0.0579%)
     
  • BTC-USD

    30,183.44
    +1,173.16 (+4.04%)
     
  • CMC Crypto 200

    669.81
    +17.58 (+2.69%)
     
  • FTSE 100

    7,302.74
    -135.35 (-1.82%)
     
  • Nikkei 225

    26,402.84
    -508.36 (-1.89%)
     

Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Sana Biotechnology Inc (NASDAQ: SANA) has obtained non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct from IASO Biotherapeutics and Innovent Biologics.

  • The constructs can be used in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications.

  • IASO Bio and Innovent will receive an upfront payment and are entitled to receive up to approximately $204 million in potential development and regulatory milestone payments across up to six products, as well as royalties.

  • Related: Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology.

  • B cell maturation antigen (BCMA) has been validated as a target for autologous CAR T therapy in relapsed and/or refractory multiple myeloma.

  • Separately, Sana Biotechnology has entered into an agreement with the National Cancer Institution (NCI) for worldwide exclusive commercial rights to the NIH's CD22 chimeric antigen receptor (CAR) with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.

  • Sana agreed to pay the NIH an upfront amount, certain milestone payments, and royalties on net sales of royalty-bearing products.

  • Price Action: SANA shares closed 3.30% lower at $12.30 on Monday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.